Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
SGHT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.03 - $6.82
Previous CloseN/A
Volume59.09K
Average Volume (3M)113.32K
Market Cap
$185.38M
Enterprise Value$153.09M
Total Cash (Recent Filing)$101.50M
Total Debt (Recent Filing)$40.57M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 06, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding52,367,360
10 Day Avg. Volume105,608
30 Day Avg. Volume113,320
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda-3.36
Forecast
1Y Price Target
$4.29Price Target Upside25.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Prescribing AccountsThe company reported a record number of prescribing accounts and strong patient volume growth, reinforcing its confidence in the durability of interventional glaucoma strength.
Product AdoptionSurgeon adoption of the OMNI Edge has been solid, with the latest iteration emphasizing usability, which is an often overlooked but critical element.
Revenue GuidanceSight Sciences raised its 2025 revenue guidance, indicating confidence in future performance.
Bears Say
Market AccessWhile market access remains a challenge, TearCare has the potential to disrupt the dry eye market should it receive reimbursement coverage.
Operating EnvironmentNear-term visibility remains limited despite navigating a challenged operating environment well.
Payer WinsThe company has not had a payer win this year and acknowledges it is behind internal expectations.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $2.03 and its highest was $6.82 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $185.38M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Aug 07, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.033.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.26.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 52,367,360 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went up 19.437%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.29 (25.07% Upside)
$4.29 (25.07% Upside)
Hedge Fund Trend
Decreased
By 11.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $258.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.62%
12-Months-Change
Fundamentals
Return on Equity
-57.10%
Trailing 12-Months
Asset Growth
-18.53%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
SGHT Company Deck
SGHT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased strong operational performance, highlighted by a raised revenue guidance and positive feedback on new technologies. However, challenges remain with the decline in Dry Eye revenue and the ongoing difficulty in securing reimbursement for TearCare. Despite these issues, the company demonstrated effective management and strategic direction, particularly in the Surgical Glaucoma segment.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$4.29
▲(25.07% Upside)
Technical Analysis
Ownership Overview
34.21% Insiders
5.55% Mutual Funds
21.43% Other Institutional Investors
32.22% Public Companies and
Individual Investors